Trademark: 90160128
Word
EUGAMM
Status
Dead
Status Code
606
Status Date
Monday, July 22, 2024
Serial Number
90160128
Mark Type
4
Filing Date
Friday, September 4, 2020
Published for Opposition
Tuesday, April 20, 2021
Abandoned Date
Monday, July 22, 2024

Trademark Owner History
Green Cross Corporation - Owner At Publication

Classifications
5 Blood plasma derivatives for medical purposes, namely, immune globulins including Rh immune globulin; Immunoglobulin preparations, namely, pharmaceutical immunoglobulin preparations for diagnosis of primary humoral immunodeficiency, common variable immune deficiency, X-linked agammaglobulinemia (XLA), hyper immunoglobulin M syndromes, Wiskott Aldrich syndrome, severe combined immune deficiency (SCID), agammaglobulinemia, hypogammaglobulinemia, inflammatory diseases, immunological disorders, bacterial infections, acute serious bacterial infection, chronic inflammatory demyelinating polyneuropathy (CIDP) and immune thrombocytopenic purpura (ITP), for preventing primary humoral immunodeficiency, Kawasaki disease, Guillain-Barre syndrome, common variable immune deficiency, X-linked agammaglobulinemia (XLA), hyper immunoglobulin M syndromes, Wiskott Aldrich syndrome and severe combined immune deficiency (SCID), agammaglobulinemia, hypogammaglobulinemia, cardiovascular disease, inflammatory diseases, immunological disorders, bacterial infections, acute serious bacterial infection, chronic inflammatory demyelinating polyneuropathy (CIDP) and immune thrombocytopenic purpura (ITP), and for treatment of primary humoral immunodeficiency, Kawasaki disease, Guillain-Barre syndrome, common variable immune deficiency, X-linked agammaglobulinemia (XLA), hyper immunoglobulin M syndromes, Wiskott Aldrich Syndrome and severe combined immune deficiency (SCID), agammaglobulinemia, hypogammaglobulinemia, cardiovascular disease, inflammatory diseases, immunological disorders, bacterial infections, acute serious bacterial infection, chronic inflammatory demyelinating polyneuropathy (CIDP) and immune thrombocytopenic purpura (ITP)

Trademark Events
Sep 8, 2020
New Application Entered
Oct 9, 2020
New Application Office Supplied Data Entered
Jan 12, 2021
Assigned To Examiner
Jan 13, 2021
Priority Action Written
Jan 13, 2021
Priority Action E-Mailed
Jan 13, 2021
Notification Of Priority Action E-Mailed
Mar 10, 2021
Correspondence Received In Law Office
Mar 11, 2021
Teas/Email Correspondence Entered
Mar 10, 2021
Teas Response To Office Action Received
Mar 12, 2021
Approved For Pub - Principal Register
Mar 31, 2021
Notification Of Notice Of Publication E-Mailed
Apr 20, 2021
Published For Opposition
Apr 20, 2021
Official Gazette Publication Confirmation E-Mailed
May 4, 2022
Sou Extension 2 Granted
Jun 15, 2021
Noa E-Mailed - Sou Required From Applicant
Nov 24, 2021
Sou Teas Extension Received
Nov 24, 2021
Sou Extension 1 Filed
Nov 24, 2021
Sou Extension 1 Granted
Nov 26, 2021
Notice Of Approval Of Extension Request E-Mailed
May 4, 2022
Sou Teas Extension Received
May 4, 2022
Sou Extension 2 Filed
Nov 15, 2022
Sou Teas Extension Received
May 6, 2022
Notice Of Approval Of Extension Request E-Mailed
Nov 13, 2023
Case Assigned To Intent To Use Paralegal
Nov 15, 2022
Sou Extension 3 Filed
Nov 15, 2022
Sou Extension 3 Granted
Nov 17, 2022
Notice Of Approval Of Extension Request E-Mailed
May 17, 2023
Sou Teas Extension Received
May 17, 2023
Sou Extension 4 Filed
May 17, 2023
Sou Extension 4 Granted
May 19, 2023
Notice Of Approval Of Extension Request E-Mailed
Nov 6, 2023
Sou Teas Extension Received
Nov 6, 2023
Sou Extension 5 Filed
Jul 22, 2024
Abandonment - No Use Statement Filed
Jul 22, 2024
Abandonment Notice E-Mailed - No Use Statement Filed
Nov 13, 2023
Sou Extension 5 Granted
Nov 14, 2023
Notice Of Approval Of Extension Request E-Mailed

Trademark Alertz updated from USPTO on 2030-01-24